Developing a new peptide drug to treat Alzheimer's disease
Official title: Multi-target Peptide Drug for Alzheimer's Disease
Funded at Alzarrok Bio LLC · NIH-10921064 · Data updated 2026-11-12
This study is testing a new drug called ALZ100, which is designed to help people with Alzheimer's by tackling several problems in the brain at once, and it will be tested in lab models to see how well it works.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Alzarrok Bio LLC NIH-funded |
| Lab location | 1 site (Midwest City, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $500,000 |
| NIH project number | 1R41AG084429-01A1 |
| Project ID | NIH-10921064 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who are seeking new treatment options.
✕Less likely to help
Patients with other forms of dementia or those who do not have Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on creating a peptide drug called ALZ100, derived from a human defense protein, to target multiple pathways involved in Alzheimer's disease. Unlike existing treatments that typically address a single aspect of the disease, ALZ100 aims to inhibit several key mediators that contribute to neurodegeneration and inflammation in the brain. The study will assess the drug's effectiveness in laboratory models to demonstrate its ability to engage and inhibit these targets, potentially leading to improved outcomes for patients with Alzheimer's.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for Alzheimer's patients by addressing multiple disease mechanisms simultaneously.
How similar studies have gone: While multitarget approaches in Alzheimer's treatment are being explored, this specific peptide drug represents a novel strategy that has not been widely tested in clinical settings.
Where this research is happening
-
Alzarrok Bio LLC
Midwest City, United States Active
Researchers
- Principal investigator: Kasus-Jacobi, Anne — Alzarrok Bio LLC
- Study coordinator: Kasus-Jacobi, Anne
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.